A retrospective clinical audit was undertaken to assess patient outcomes following treatment for vulval cancer for all patients treated over the last 15 years at the Royal Women's Hospital. 112 patients were identified. Outcomes assessed included: recurrence, disease free survival and quality of life. For all recurrences, histopathology reports were reviewed for predisposing risk factors including evidence of premalignant conditions and presence of lymphovascular space invasion. Of the 112 patients treated, 17 (15.5%) recurred; 7 local, 5 groin and 4 both local and groin. One patient recurred with only distant disease. All patients who recurred only at the groin were sentinel lymph node positive at the time of initial treatment. Time to recurrence varied from months to years. The low rate of recurrence is likely attributable to only short-term follow-up data being available for some patients. Histopathological features including premalignant conditions were frequently seen in patients who recurred.